网站主页>>>研发精选>>>临床前CDMO研发筛选相关化合物
CDMO是Contract Development and Manufacturing Organization的缩写,即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药(特别是创新药)工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力,是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化:创新性合成路线设计、工艺参数优化. 2, 中试放大:实验室工艺向规模化生产的转化 3, 注册批生产:支持客户新药申报的验证批生产. 4, 商业化生产:药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测:2026年全球CDMO市场规模:预计达1,189亿美元 2033年全球CDMO市场规模:预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物,已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前,在多肽、ADC、CGT等新型药物赛道的驱动下,全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力,全球市占率有望持续提升,行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

示例图片

临床前CDMO研发化合物筛选

  • Tamoxifen (ICI 46474)

    中文名称: 他莫昔芬
    CAS号:10540-29-1
    分子式: C26H29NO 分子量: 371.51
    产品形式: Free Base
    研发状态: Not yet recruiting
    研发用途: Metastatic Breast Cancer; Tumor; Muscle Neoplasms; Chronic Pain
    研究机构: DR. DIANE CHISESI NFS. MD. PHD.; IRB; Paradyne Networks A Foundation
    研发日期: Jul-24
    研发阶段: --
    Tamoxifen (ICI 46474, (Z)-Tamoxifen, trans-Tamoxifen) is a selective estrogen receptor modulator (SERM). Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen induces apoptosis.

  • Dolutegravir (GSK1349572)

    中文名称:度鲁特韦
    CAS号:1051375-16-6
    分子式: C20H19F2N3O5 分子量: 419.38
    产品形式: free base
    研发状态: Not yet recruiting
    研发用途: Pediatric HIV Infection; Latent Tuberculosis
    研究机构: Brigham and Women''s Hospital; APIN Public Health Initiatives; University of Cape Town
    研发日期: May-24
    研发阶段: Phase 1
    Dolutegravir (GSK1349572,S/GSK1349572,Tivicay) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

  • Cabotegravir (GSK1265744)

    中文名称:卡替拉韦
    CAS号:1051375-10-0
    分子式: C19H17F2N3O5 分子量: 405.35
    产品形式: free base
    研发状态: Recruiting
    研发用途: Oral Pre-exposure Prophylaxis (PrEP); Long-acting Injectable Cabotegravir for PrEP
    研究机构: Georgetown University; AIDS Vaccine Advocacy Coalition; Centers for Disease Control and Prevention; Center for the Development of People; Cooper/Smith; Elizabeth Glaser Pediatric AIDS Foundation; Family Health Services; Healthqual; Johns Hopkins Research Project Malawi; Johns Hopkins Bloomberg School of Public Health; Kamuzu University of Health Sciences; Blantyre District Health Office Malawi; Lilongwe District Health Office Malawi; Lighthouse Trust; Ministry of Health Malawi; National AIDS Commission Malawi; Pakachere Institute of Health and Development Communication; Partners in Hope; Population Services International; University of North Carolina; United States Agency for International Development (USAID); United States President''s Emergency Plan for AIDS Relief; Quantitative Engineering Design; Clinton Health Access Initiative-Malawi
    研发日期: March 26 2024
    研发阶段: --
    Cabotegravir (GSK744, GSK1265744, S/GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.

  • Balixafortide (POL6326)

    中文名称:拮抗剂多肽BALIXAFORTIDE
    CAS号:1051366-32-5
    分子式: C84H118N24O21S2 分子量: 1864.11
    产品形式: Free base
    研发状态: Withdrawn
    研发用途: Advanced Breast Cancer
    研究机构: MedSIR
    研发日期: March 16 2022
    研发阶段: Phase 1 : Phase 2
    Balixafortide (POL6326) is an orally bioavailable peptidic CXC chemokine receptor 4 (CXCR4) antagonist.

  • Finerenone

    中文名称:(4S)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-1,4-二氢-2,8-二甲基-1,6-萘啶-3-甲酰胺(非奈利酮杂质)
    CAS号:1050477-31-0
    分子式: C21H22N4O3 分子量: 378.42
    产品形式: Free base
    研发状态: Not yet recruiting
    研发用途: Asthma; Asthma in Children; Allergy; Rhinitis Allergic; Atopic Dermatitis; Allergen Immunotherapy
    研究机构: Tampere University; Professor Lauri Lehtimäki; Professor Mika Mäkelä; Professor Sanna Toppila-Salmi; Professor Ilkka Junttila
    研发日期: Oct-24
    研发阶段: --
    Finerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.

  • Tacrolimus (FK506)

    中文名称:他克莫司
    CAS号:104987-11-3
    分子式: C44H69NO12 分子量: 804.02
    产品形式: free base
    研发状态: Not yet recruiting
    研发用途: Hyperglycemia; Renal Transplant Complication Primary Non-Function; Diabetes
    研究机构: Rigshospitalet Denmark; Aarhus University Hospital; Odense University Hospital
    研发日期: April 1 2024
    研发阶段: Phase 4
    Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. Tacrolimus also inhibits the phosphatase activity of calcineurin. Tacrolimus induces vascular endothelial autophagy.

  • 免费注册, 助力研发,生产, 销售.

    招募中心

    我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!

    即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.

    试运营阶段,所有广告业务5折优惠

    分类广告投放

    依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.

    客户展示

    示例图片
    优秀企业推荐
    ×

    通知